Figure 8.

Combined therapy of in situ iPSC-DC injection and RT renders tumors responsive to anti-PD-L1 therapy, has potential to eradicate poorly T cell-inflamed tumors, and establishes immunological memory. (A) Experimental set-up. Mice bearing AT-3 tumors in the left fourth mammary gland were treated with intratumoral iPSC-DC injections, RT, and anti-PD-L1 antibody (αPD-L1 Ab) or isotype Ab. (B) Tumor growth curves (individual) in AT-3 tumor-bearing mice in different treatment groups as indicated (n=5–9). (C) Survival curves in AT-3 tumor-bearing mice in different treatment as indicated. (D) Naïve mice and surviving mice from the experiment (B, C) were rechallenged with AT-3 and MC38 in the right flank at day 123 (AT-3) and on back at day 127 (B16), respectively. NS not significant, **p<0.01, ***p<0.001, ****p=0.0001 by a log-rank test (C). Mean±SEM. Data shown are representative of two independent experiments. i.p., intraperitoneally; iPSC-DC, induced pluripotent stem cell-derived dendritic cells; i.t., intratumorally; PD-L1, PD-1 ligand 1; RT, radiotherapy.